Form 51-102F3

Material Change Report

1. Name and Address of Company

Auricle Biomedical Corporation ("Auricle" or the "Company")
208 – 5455 West Boulevard
Vancouver, British Columbia V6M 3W5

2. Date of Material Change

April 21, 2008

3. News Release

A new release was issued on April 21, 2008 through the facilities of CNW Group and filed with regulatory authorities in Canada.

4. Summary of Material Change

Auricle has completed its initial public offering of 2,000,000 common shares at $0.10 per share for gross proceeds of $200,000 pursuant to a prospectus dated January 28, 2008.

5. Full Description of Material Change

Auricle has completed its initial public offering of 2,000,000 common shares at $0.10 per share for gross proceeds of $200,000 pursuant to a prospectus dated January 28, 2008. Canaccord Capital Corporation ("Canaccord"), acting as agent for the offering, received a cash commission of 10% and the Company granted agent's options to Canaccord to purchase up to an aggregate of 200,000 common shares from the date the Company's common shares are listed on the TSX Venture Exchange (the "Exchange").

The Company's common shares have been conditionally approved for listing on the Exchange.

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information

None.

8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change and may be contacted by any securities commission regarding the change.

Punit Dhillon
Chief Financial Officer

Telephone: 604.263.8877
Facsimile: 858.777.5481

9. Date of Report

April 21, 2008